Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Dermapen

Also known as: DermapenWorld, Dermapen 4, DP4

Dermapen is a brand of powered microneedling devices used to improve skin appearance. Its professional Dermapen 4 system makes small punctures using a disposable needle cartridge; the DP4 model has human evidence for facial acne scars. DermapenWorld also sells separate home-use devices and skincare.

In plain English — Dermapen is a brand of devices that use moving fine needles to make small punctures in the skin. Some adults' facial acne scars improved in small studies of its professional DP4 device. Suitability depends on the specific device, the skin concern and the person's medical history.

Evidence status

Manufacturer-supported

Small human studies for the professional DP4 model. The DP4 FDA submission reports improvement in facial acne scars in two small, uncontrolled human cohorts with short follow-up. These are commercially submitted data, with the second study explicitly sponsor-conducted, rather than independent comparative trials. The named US clearance, UK product requirements and practitioner scope are separate questions.

What Dermapen is, and the types available#

Dermapen is a powered microneedling brand within DermapenWorld’s device, skincare and training range. The company describes an Australian origin and founding by Stene Marshall in 2010. Its professional Dermapen 4 system, separate home-use devices and Dp Dermaceuticals skincare have different roles within that range.[1]

The professional DP4 model described in FDA submission K221070 uses a cartridge of 16 fine needles, a powered handpiece and a protective sleeve. It produces mechanical punctures rather than radiofrequency heating. The subject here is that named system and its evidence; the wider procedure is covered in the microneedling guide.[2]

A brand advertisement in June 2025 announced direct UK distribution under DermapenWorld UK Limited. Companies House records that active company as number 11016290, formerly Equipmed Europe Limited. Equipmed USA LLC is separately named as the DP4 FDA applicant. These are identifiable commercial roles; the records do not establish an ultimate global ownership chain.[3, 4][2]

Use of Dermapen in aesthetic practice#

In the US, K221070 covers a prescription DP4 device for improving the appearance of facial acne scars in adults aged 22 or older with Fitzpatrick skin types I–V. In Great Britain, medical-device placement requires the applicable registration and conformity route, including current provisions recognising CE-marked devices; Northern Ireland operates under the EU MDR framework. The model’s current market documentation and instructions are therefore part of procurement and clinical governance.[2][7]

Practitioner and premises requirements are separate from product-market status. As checked on 16 September 2026:

  • England:the DHSC’s 2025 response describes further consultation and implementation work for licensing and higher-risk restrictions. It is a policy programme, not a completed UK-wide operator scheme.[8]
  • Scotland: the 2026 licensing order includes non-RF needling below 1.5 mm, subject to exceptions, with its licence requirement deferred until 6 September 2027 and transition provisions. The separate Act includes non-RF needling at 1.5 mm or more; relevant anaesthetic, injection and service exceptions also matter. Its initial commencement instrument brought definitions and powers into force, not the full age and premises offences; the section 3 premises offence cannot commence before 6 September 2027. These are statutory distinctions, not recommended treatment depths.[9, 10, 11]
  • Wales: the current special-procedure scheme covers acupuncture, piercing, electrolysis and tattooing. It should not be treated as a blanket permission or prohibition for every microneedling service; the actual procedure and applicable local, healthcare and professional requirements need checking.[12]i
  • Northern Ireland: an April 2026 ministerial answer reported no current plan within the remaining mandate for a broad cosmetic-procedure licensing scheme. Existing independent-healthcare oversight through RQIA remains a separate, service-specific consideration.[13, 14]

Contraindications and cautions#

Suitability rests on the person’s medical history and skin examination alongside the current instructions for the model and market. The FDA’s general microneedling guidance flags active infection or facial rash, immune suppression, uncontrolled diabetes, bleeding disorders or anticoagulant treatment, keloid history and relevant metal or anaesthetic allergy. These are class-level assessment concerns, not a substituted Dermapen 4 instruction manual.[6]i

The same guidance flags pregnancy and breastfeeding as circumstances in which needling may be unsuitable. Neither the small DP4 scar cohorts nor a brand’s product range establishes suitability for those populations. Active acne, a suspected lesion or raised scarring needs its own assessment before a facial scar procedure is selected.[2, 6]

Clinical uses and the evidence behind them#

Adult facial acne scars

The most directly inspectable DP4 clinical evidence is in the manufacturer’s FDA submission. Its first uncontrolled study included 22 adults aged 23–55 with facial atrophic acne scars and Fitzpatrick types I–V. At the two-session assessment, four weeks after treatment, three masked photographic evaluators recorded mean improvements on the Acne Scar Assessment Scale of 1.2 grades (95% CI 0.8–1.5), 1.6 (1.2–1.9) and 1.5 (1.1–1.9). These are changes within the treated cohort, not differences from a control group.[2][2]

A second, explicitly sponsor-conducted study included 20 adults aged 21–67, Fitzpatrick II–IV. Four weeks after three sessions, its mean scar score was 1.53 compared with 2.58 at baseline. The final US indication nevertheless begins at age 22. Both cohorts provide a positive clinical signal, but their small size, lack of a control group and manufacturer-submission provenance limit causal interpretation. Masking evaluators is useful; it does not supply an untreated comparison.[2][2]i

Other concerns and products

DermapenWorld promotes a wider system of devices and supporting skincare. The professional DP4 scar findings do not automatically establish outcomes for its home devices, individual skincare products, pigmentation or wrinkles. A proposed service needs evidence and instructions relevant to its actual indication and components. The acne-scarring entry places needling among options for different scar patterns.[1, 2]i

Selecting a Dermapen system#

Selection begins with the skin concern, the exact device and the supplier’s current documentation. Useful checks include the model’s intended use, applicable conformity documents, current instructions, compatible genuine cartridges and servicing arrangements. Practitioner training, safe handling and a documented complication pathway are as relevant as the handpiece specification.[2, 6, 7]i

The DP4 submission describes sterile single-use cartridges and a barrier sleeve. A fresh cartridge is required for each patient and each session; device cleaning and component handling follow the applicable instructions. Needle settings, anaesthetic decisions and accompanying products are governed by the actual system and clinical assessment, not by a generic brand-name recipe.[2, 6]

For “Dermapen versus SkinPen”, a useful starting point is the exact indication:

Named US model and recordLabelled scope relevant to this comparison
DP4, K221070Facial acne-scar appearance, Fitzpatrick I–V, adults 22 or older.
SkinPen Precision Elite, K241400Facial acne-scar appearance across all Fitzpatrick types; neck wrinkles in types II–IV; adults 22 or older.

These are the specified US records, not a statement about every generation or country’s labelling. The evidence-comparison question is addressed under commonly misstated claims below; SkinPen covers that system separately.[2, 5]

Product delivery also has its own scope. The FDA’s aesthetic microneedling classification does not include transdermal delivery of cosmetics, medicines or biologics. In the US, the acne-scar clearance therefore cannot be used to validate every proposed needling-and-product combination; other markets require their own applicable assessment.[2, 6]

Adverse effects and their management#

Expected treatment reactions:the first DP4 cohort recorded redness, discomfort, pain, peeling and dryness. In the second, mean pain was 5.7/10, ranging from 4–7, and staff rated erythema as severe in nine of 20 participants. The cohorts show that discomfort and visible recovery vary; their observations are not a guaranteed downtime schedule.[2]

Reactions needing assessment:one participant in the second cohort had excessive swelling that resolved within 96 hours. Separately, FDA class guidance lists infection, pigment change and cold-sore reactivation among less common needling risks. These class warnings do not provide DP4-specific complication rates. Unexpected, worsening or persistent symptoms require prompt clinical assessment through the practitioner’s complication pathway, rather than simply continuing the course.[6][2]

Referral and scope boundaries#

Active acne and its residual scars are different clinical problems. NICE recommends a specialist pathway for diagnostic uncertainty or nodulocystic acne and consideration of referral when acne is causing scars, persistent pigment changes or substantial psychological distress. A request for Dermapen should not delay that assessment.[15]i

Keloid history, suspicious lesions and uncertain raised scars also warrant clinical assessment before selecting needling. The professional responsible for the procedure needs competence to recognise and respond to complications and a route to timely medical care. See keloid and hypertrophic scarring for that differential.[6]

Mechanism of action#

DP4’s motor drives a cartridge of fine needles to produce repeated mechanical punctures in skin. Unlike RF microneedling, the device described in K221070 does not add radiofrequency energy. The submitted human studies assessed scar appearance rather than a measured percentage increase in collagen. Device penetration testing included porcine skin, which is a separate experimental model, not a human clinical outcome.[2]i

Commonly misstated claims#

Regulatory terminology

Heard claim:“Dermapen is FDA-approved.”

Literature finding: the actual DP4 record is a 510(k) substantial-equivalence determination for a named device and defined indication. It is not a premarket-approval decision for the whole brand.[2]

Supported statement: DP4 is FDA-cleared under K221070 for its specified US use.[2]

Scar improvement percentages

Heard claim:“The study showed 77% scar removal.”

Literature finding: one evaluator judged 17 of 22 participants to have at least one grade of improvement: 77% (95% CI 54–92%). Other evaluators gave different response proportions. The denominator is people meeting a rating threshold, not the percentage of each person’s scarring removed.[2]

Supported statement: the small cohort showed improvement in scar ratings, with uncertainty and assessor variation; it did not establish 77% scar removal.[2]

Comparative superiority

Heard claim:“The clearance or needle specification proves Dermapen is better than SkinPen.”

Literature finding:the original submissions establish their named regulatory positions, including DP4’s predicate comparison and Elite’s bridge to an earlier SkinPen model. They are not a randomised clinical comparison of the two current systems.[2, 5] No current-model DP4-versus-SkinPen clinical head-to-head was located.[no source found]

Supported statement: compare the documented models, indications and evidence; a clinical superiority ranking was not established by this review.

Areas of remaining uncertainty#

  • Durability and repeat treatment: longer follow-up of defined scar populations would clarify maintenance needs; short-term photographic gains should not become a promise of permanent correction.[2]
  • Predicting an individual’s outcome: larger studies stratified by scar morphology and skin type would help selection; the existing small subgroups cannot supply a dependable personalised success percentage.[2]
  • Whole-service contributions: separately evaluating devices and accompanying products would clarify which component contributes what; outcomes should be recorded against the actual service rather than the brand name alone.[1, 2]

Frequently asked questions#

Is Dermapen a procedure or a device?

It is a brand of devices and associated products. Microneedling is the procedure; the particular professional or home model identifies what is actually being used.[1, 2]

What information helps assess a proposed treatment?

The exact model, intended concern, current instructions, relevant medical history and baseline skin findings help determine suitability. For scar work, recording photographs, concurrent treatment and adverse experiences makes later review more interpretable.[2, 6]i

Where do settings and aftercare come from?

The current instructions for the specific system, together with the treating professional’s clinical assessment and applicable scope, govern them. This reference describes the device and its evidence rather than providing a treatment protocol.[2, 6]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. DermapenWorld. About DermapenWorld: professional brand, device, training and skincare information. Accessed 16 September 2026.Tier 4Supports: The brand's account of its Australian origin, Stene Marshall's founding in 2010, professional devices, home devices, Dp Dermaceuticals and training ecosystem.Funding / interest: Brand-authored commercial material. Its product descriptions and reported history are not independent efficacy or ownership-chain evidence.
  2. US Food and Drug Administration. K221070: DP4 Microneedling device, Equipmed USA LLC. Substantial-equivalence determination 20 December 2022; manufacturer summary prepared 19 December 2022.Tier 1Supports: Exact US facial-acne-scar indication, adult age and phototype scope, technical configuration, two small uncontrolled human cohorts, assessor outcomes with reported confidence intervals and adverse experiences.Funding / interest: FDA determination with a manufacturer-authored Equipmed USA LLC submission. Study 2 is explicitly sponsor-conducted; the summary does not establish independent funding or supply a separate funding declaration for study 1. Tier 1 describes regulatory authority, not the clinical certainty of the embedded cohorts.
  3. DermapenWorld UK. Brand advertisement announcing direct UK distribution. Dentistry Connected, June 2025, PDF page 9, naming DermapenWorld UK Limited.Tier 4Supports: The brand's publicly stated direct UK distribution role and the named UK company at that date; not an exclusive contract or ultimate ownership chain.Funding / interest: Brand-authored commercial advertisement in an event publication, not independent corporate investigation or clinical evidence.
  4. Companies House. DERMAPENWORLD UK LIMITED, company number 11016290: company overview and previous names. Accessed 16 September 2026.Tier 1Supports: Active registered company, incorporation 17 October 2017 and former name Equipmed Europe Limited until 18 July 2023.Funding / interest: Official corporate register containing company-filed information. Companies House states that it does not check the accuracy of information filed; no clinical sponsorship claim is involved.
  5. US Food and Drug Administration. K241400: SkinPen Precision Elite, Bellus Medical LLC dba Crown Aesthetics. Substantial-equivalence determination 29 August 2024.Tier 1Supports: Named Elite facial-acne-scar and neck-wrinkle indications with age/phototype limits; bridge to SkinPen Precision K220506 without new clinical testing for Elite.Funding / interest: FDA determination and manufacturer-authored commercial submission. Regulatory comparison does not provide a Dermapen-versus-SkinPen clinical trial.
  6. US Food and Drug Administration. Microneedling Devices. Updated 15 October 2025; accessed 16 September 2026.Tier 1Supports: Class-level device descriptions, suitability cautions, common and less common risks, cartridge safety, practitioner training, complication escalation and US product-delivery scope.Funding / interest: US regulator's device information; no manufacturer sponsorship stated. This is class guidance, not a current Dermapen 4 UK instruction manual or a comparative safety study.
  7. Medicines and Healthcare products Regulatory Agency. Regulating medical devices in the UK. Updated 20 February 2026; accessed 16 September 2026.Tier 1Supports: GB medical-device registration/conformity with CE transitional recognition versus NI EU MDR framework; product-market scope rather than operator licensing.Funding / interest: UK government regulatory guidance; no commercial manufacturer sponsorship stated.
  8. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation response. 7 August 2025.Tier 1Supports: England-specific programme for further consultation and implementation of licensing/restrictions, not a completed UK-wide operator scheme.Funding / interest: Government consultation response; no manufacturer sponsorship. Policy development, not a clinical study or enacted final classification.
  9. Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act 2026, asp 13. Sections 1–5 and 24; schedule 1.Tier 1Supports: Scottish statutory categories, including non-RF needling at 1.5 mm or more, relevant exceptions and earliest possible commencement of the section 3 premises offence.Funding / interest: Primary legislation; no commercial sponsorship. Enacted provisions must be read with commencement instruments.
  10. Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act 2026 (Commencement No. 1 and Saving Provision) Regulations 2026, S.S.I. 2026/206.Tier 1Supports: Provisions brought into force on 22 July 2026; definitions and powers are not commencement of the full age and premises offences.Funding / interest: Primary statutory instrument; no commercial sponsorship.
  11. Civic Government (Scotland) Act 1982 (Licensing of Non-surgical Procedures) Order 2026, S.S.I. 2026/87. Articles 3–6 and schedule 1.Tier 1Supports: Non-RF needling below 1.5 mm within defined scope; licence requirement deferred until 6 September 2027, with transition and exceptions.Funding / interest: Primary statutory instrument; no commercial sponsorship.
  12. Welsh Government. Licensing scheme for special procedures. Updated 30 July 2026.Tier 1Supports: Welsh individual licensing and premises approval for the four designated special-procedure categories; not a blanket microneedling operator rule.Funding / interest: Welsh Government regulatory guidance; no manufacturer sponsorship stated.
  13. Northern Ireland Assembly. Minister of Health answer to AQW 41857/22-27, 1 April 2026.Tier 1Supports: Dated NI policy statement: no current plans in the remaining mandate for a broad non-surgical-cosmetic licensing scheme.Funding / interest: Official parliamentary answer; no commercial sponsorship. A policy statement is not an exemption from existing law.
  14. Regulation and Quality Improvement Authority. Registration Guidance. Accessed 16 September 2026.Tier 1Supports: Existing NI oversight of independent clinics and hospitals; applicability depends on the service.Funding / interest: NI health and social-care regulator guidance; no manufacturer sponsorship stated.
  15. National Institute for Health and Care Excellence. Acne vulgaris: management. NG198, recommendations 1.4.1–1.4.5. Accessed 16 September 2026.Tier 1Supports: Clinical referral pathways for diagnostic uncertainty, nodulocystic acne, scarring, persistent pigment change and substantial psychological distress.Funding / interest: NICE public evidence-based guideline development; no Dermapen manufacturer sponsorship identified on the recommendations page.